Family Medicine Doctors in Solvang, CA Accepting Medicare

5 Family Medicine doctors found. Showing 1 - 5

Dr. Alan Richard Hersh, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2027 Village Ln, Suite 102, Solvang, CA 93463 Phone: 805-688-3440    Fax: 805-686-5694

Robert L. Gottesman, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 1730 Lewis St, Solvang, CA 93463 Phone: 805-688-8299

Dr. James Kevin Beckmen, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2027 Village Ln Ste 102, Solvang, CA 93463 Phone: 805-688-3440    Fax: 805-681-1768

Dr. Marlene E Roberts, PHD, FNP Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2027 Village Ln Ste 102, Solvang, CA 93463 Phone: 805-681-7700

Allison Akers, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2027 Village Ln Ste 102, Solvang, CA 93463 Phone: 805-688-3440

News Archive

Combination of biomarkers indicates high risk of Alzheimer's in the future

Physician Oskar Hansson and his research group are studying biomarkers - substances present in spinal fluid and linked to Alzheimer's disease. The group has studied close to 140 people with mild memory impairment, showing that a certain combination of markers (low levels of the substance beta-amyloid and high levels of the substance tau) indicate a high risk of developing Alzheimer's disease in the future.

RXi Pharmaceuticals to present data on rxRNA therapeutic platform development at upcoming conferences

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that senior members of its management will be presenting at upcoming conferences and will highlight critical aspects of the development of RXi's next generation rxRNA™ therapeutic platform as well as specific preclinical data generated with this platform.

Genzyme reports five-year patient data from Phase 2 multiple sclerosis trial

Genzyme Corporation today reported five-year patient data from its completed Phase 2 multiple sclerosis (MS) trial. This sub-group analysis found that nearly 90 percent of alemtuzumab-treated patients were free of sustained accumulation of disability, and that patients receiving alemtuzumab also maintained improved mean disability scores and a low risk of relapse over the 60-month follow-up period.

IPG Photonics fourth quarter revenues increase 86% year-over-year to $101 million

IPG Photonics Corporation today reported financial results for the fourth quarter of fiscal 2010 ended December 31, 2010.

FDA seeks permanent injunction against dietary supplement manufacturer James G. Cole

The U.S. Food and Drug Administration, in a complaint filed by the U.S. Department of Justice, is seeking a permanent injunction against the dietary supplement manufacturer James G. Cole, Inc., its president, James G. Cole, and its general manager, Julie D. Graves, following the company's repeated distribution of unapproved drugs and adulterated dietary supplements in violation of the Federal Food, Drug, and Cosmetic Act.

Read more Medical News

› Verified 5 days ago